Many groups have contributed to this, but the group of Kaj Blennow and his colleague Henrik Zetterburg have really led the field in establishing markers of pathology, including the levels of amyloid-beta, which decrease in CSF in AD, and microtubule-associated protein tau and phosho-tau levels, which increase in CSF in this condition [3]. The gene discussed is MAPT; the disease is Alzheimer disease.